PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism

Reference

• Sica A, Saccani A, Mantovani A. Tumor-associated macrophages: a molecular perspective. Int Immunopharmacol 2002; 2:1045-54; PMID:12349942; http://dx.doi.org/10.1016/S1567-5769(02)00064-4
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metast Rev 2007; 26:373-400; PMID:17717638; http://dx.doi.org/10.1007/s10555-007-9072-0
   PubMed Web of Science ®Google Scholar
• Wang Q, Ni H, Lan L, Wei X, Xiang R, Wang Y. Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Res 2010; 20:701-12; PMID:20386569; http://dx.doi.org/10.1038/cr.2010.52
   PubMed Web of Science ®Google Scholar
• Li J. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-7; PMID:9072974; http://dx.doi.org/10.1126/science.275.5308.1943
   PubMed Web of Science ®Google Scholar
• Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15:356-62; PMID:9090379; http://dx.doi.org/10.1038/ng0497-356
   PubMed Web of Science ®Google Scholar
• Georgescu MM. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 2010; 1:1170-7; PMID:21779440; http://dx.doi.org/10.1177/1947601911407325
   PubMedGoogle Scholar
• Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16:525-37; PMID:15728109; http://dx.doi.org/10.1093/annonc/mdi113
   PubMed Web of Science ®Google Scholar
• Tamura M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280:1614-7; PMID:9616126; http://dx.doi.org/10.1126/science.280.5369.1614
   PubMed Web of Science ®Google Scholar
• Hsu CJ, Wu MH, Chen CY, Tsai CH, Hsu HC, Tang CH. AMP-activated protein kinase activation mediates CCL3-induced cell migration and matrix metalloproteinase-2 expression in human chondrosarcoma. Cell Commun Signal 2013; 11:68-83; PMID:24047437; http://dx.doi.org/10.1186/1478-811X-11-68
   PubMed Web of Science ®Google Scholar
• Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, Luu T, Li AX, Wu X, Ye W, et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res 2012; 72:2768-79; PMID:22472119; http://dx.doi.org/10.1158/0008-5472.CAN-11-3567
   PubMed Web of Science ®Google Scholar
• Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010; 21:41-8; PMID:20005149; http://dx.doi.org/10.1016/j.cytogfr.2009.11.009
   PubMed Web of Science ®Google Scholar
• Tarassishin L, Lim J, Weatherly DB, Angeletti RH, Lee SC. Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression. J Proteomics 2014; 99:152-68; PMID:24503185; http://dx.doi.org/10.1016/j.jprot.2014.01.024
   PubMed Web of Science ®Google Scholar
• Ohnuki H, Jiang K, Wang D, Salvucci O, Kwak H, Sanchez-Martin D, Maric D, Tosato G. Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-beta signaling to drive malignant progression. Cancer Res 2014; 74:2038-49; PMID:24520074; http://dx.doi.org/10.1158/0008-5472.CAN-13-3118
   PubMed Web of Science ®Google Scholar
• Bao B, Ali S, Ahmad A, Azmi AS, Li Y, Banerjee S, Kong D, Sethi S, Aboukameel A, Padhye SB, et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PloS One 2012; 7:e50165; PMID:23272057; http://dx.doi.org/10.1371/journal.pone.0050165
   PubMed Web of Science ®Google Scholar
• Perrot-Applanat M, Di Benedetto M. Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion. Cell Adhesion Migr 2012; 6:547-53; PMID:23257828; http://dx.doi.org/10.4161/cam.23332
   PubMed Web of Science ®Google Scholar
• Yang Y, Qin J, Lan L, Li N, Wang C, He P, Liu F, Ni H, Wang Y. M-CSF cooperating with NFkappaB induces macrophage transformation from M1 to M2 by upregulating c-Jun. Cancer Biol Ther 2014; 15:99-107; PMID:24100343; http://dx.doi.org/10.4161/cbt.26718
   PubMed Web of Science ®Google Scholar
• Davis AS, Vergne I, Master SS, Kyei GB, Chua J, Deretic V. Mechanism of inducible nitric oxide synthase exclusion from mycobacterial phagosomes. PLoS Pathog 2007; 3: e186; PMID:18069890; http://dx.doi.org/10.1371/journal.ppat.0030186
   PubMedGoogle Scholar
• Cheng J, Huo DH, Kuang DM, Yang J, Zheng L, Zhuang SM. Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. Cancer Res 2007; 67:5141-7; PMID:17545592; http://dx.doi.org/10.1158/0008-5472.CAN-06-4763
   PubMed Web of Science ®Google Scholar
• Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS, Waes CV, Kulkarni AB. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 2012; 31:3322-32; PMID:22037217; http://dx.doi.org/10.1038/onc.2011.494
   PubMed Web of Science ®Google Scholar
• Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G, Georgescu MM. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene 2012; 31:1264-74; PMID:21804599; http://dx.doi.org/10.1038/onc.2011.324
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Morales FC, Kreimann EL, Georgescu MM. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J 2006; 25:910-20; PMID:16456542; http://dx.doi.org/10.1038/sj.emboj.7600979
   PubMed Web of Science ®Google Scholar
• Molina JR, Morales FC, Hayashi Y, Aldape KD, Georgescu MM. Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. Cancer Res 2010; 70:6697-703; PMID:20736378; http://dx.doi.org/10.1158/0008-5472.CAN-10-1271
   PubMed Web of Science ®Google Scholar
• Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 2001; 276:48627-30; PMID:11707428; http://dx.doi.org/10.1074/jbc.C100556200
   PubMed Web of Science ®Google Scholar
• Gomes AM, Soares MV, Ribeiro P, Caldas J, Povoa V, Martins LR, Melão A, Serra-Caetano A, de Sousa AB, Lacerda JF, et al. Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels. Haematologica 2014; 99:1062-8; PMID:24561792; http://dx.doi.org/10.3324/haematol.2013.096438
   PubMed Web of Science ®Google Scholar
• Cambien B. Signal transduction involved in MCP-1-mediated monocytic transendothelial migration. Blood 2001; 97:359-66; PMID:11154209; http://dx.doi.org/10.1182/blood.V97.2.359
   PubMed Web of Science ®Google Scholar
• Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, Gonzalez MV. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer J 2005; 114:242-8; PMID:15543611; http://dx.doi.org/10.1002/ijc.20711
   PubMed Web of Science ®Google Scholar
• Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009; 100:1385-92; PMID:19401698; http://dx.doi.org/10.1038/sj.bjc.6605017
   PubMed Web of Science ®Google Scholar
• Georgescu MM. NHERF1: molecular brake on the PI3K pathway in breast cancer. Breast Cancer Res 2008; 10:106-7; PMID:18430260; http://dx.doi.org/10.1186/bcr1992
   PubMed Web of Science ®Google Scholar
• Morales FC, Takahashi Y, Momin S, Adams H, Chen X, Georgescu MM. NHERF1/EBP50 head-to-tail intramolecular interaction masks association with PDZ domain ligands. Mol Cell Biol 2007; 27:2527-37; PMID:17242191; http://dx.doi.org/10.1128/MCB.01372-06
   PubMed Web of Science ®Google Scholar
• Yang L, Wang Y, Chen P, Hu J, Xiong Y, Feng D, Liu H, Zhang H, Yang H, He J. Na(+)/H(+) exchanger regulatory factor 1 (NHERF1) is required for the estradiol-dependent increase of phosphatase and tensin homolog (PTEN) protein expression. Endocrinology 2011; 152:4537-49; PMID:21990315; http://dx.doi.org/10.1210/en.2011-1207
   PubMed Web of Science ®Google Scholar
• Pan Y, Weinman EJ, Dai JL. Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells. Breast Cancer Res 2008; 10:R5; PMID:18190691; http://dx.doi.org/10.1186/bcr1846
   PubMedGoogle Scholar
• Georgescu MM, Morales FC, Molina JR, Hayashi Y. Roles of NHERF1/EBP50 in cancer. Curr Mol Med 2008; 8:459-68; PMID:18781953; http://dx.doi.org/10.2174/156652408785748031
   PubMed Web of Science ®Google Scholar
• Cardone RA, Greco MR, Capulli M, Weinman EJ, Busco G, Bellizzi A, Casavola V, Antelmi E, Ambruosi B, Dell'Aquila ME, et al. NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains. Mol Biol Cell 2012; 23:2028-40; PMID:22496422; http://dx.doi.org/10.1091/mbc.E11-11-0911
   PubMed Web of Science ®Google Scholar
• Li X, Xu Q, Wu Y, Qinqiao F. A CCL2/ROS autoregulation loop is critical for cancer associated fibroblasts-enhanced tumor growth of oral. Carcinogenesis 2014; 35:1362-70; PMID:24531940; http://dx.doi.org/10.1093/carcin/bgu046
   PubMed Web of Science ®Google Scholar